{
    "nct_id": "NCT03523975",
    "official_title": "Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma",
    "inclusion_criteria": "* Age ≥18 years\n* Diagnosis of mantle cell lymphoma (MCL) established by histologic assessment\n* Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL\n* ECOG Performance Status (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death) less or equal to 2\n* All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program\n* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.\n* Men and Women of childbearing potential on appropriate contraception\n* Adequate organ function\n* Ability to understand and the willingness to sign a written informed consent.\n* Ability to swallow oral capsules/tablets\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment for MCL with chemotherapy\n* Pregnant or breastfeeding women\n* Grade 2 or higher peripheral neuropathy\n* Known history of CNS (Central Nervous System) or leptomeningeal by MCL prior to study enrollment\n* Significant cardiovascular disease\n* Any condition that might significantly impair drug absorption as determined by the investigator\n* Uncontrolled active systemic fungal, bacterial, viral, or other infection, or intravenous anti-infective treatment within 2 weeks before first dose of study drug\n* History of stroke or intracranial hemorrhage within 6 months of 1st dose of study drug\n* Concurrent participation in another clinical trial\n* Subject has received a moderate or strong CYP3A inhibitor or inducer within 1 week prior to treatment initiation.\n* Psychiatric illness or social situations that would limit compliance with study requirements\n* Subject has known positivity to HIV\n* Active infection with Hepatitis B or C virus as determined by a detectable viral load on PCR.\n* Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to< 2 years.",
    "miscellaneous_criteria": ""
}